Summary of outcomes of patients with APL according to BAALC expression
| . | No. (%) . | CR % . | OS . | DFS . | CIR . | |||
|---|---|---|---|---|---|---|---|---|
| No. . | 5-y % (95% CI) . | No. . | 5-y % (95% CI) . | No. . | 5-y % (95% CI) . | |||
| All patients | 221 (100) | |||||||
| Low BAALC expression | 89 | 110 | 82 (70, 90) | 89 | 95 (86, 98) | 87 | 5 (1, 10) | |
| High BAALC expression | 79 | 111 | 73 (63, 81) | 96 | 78 (66, 86) | 91 | 21 (11, 30) | |
| P | .067 | .077 | .009* | .01* | ||||
| Low-risk patients | 39 (17) | |||||||
| Low BAALC expression | 87 | 19 | 93 (63, 99) | 14 | 100 | 13 | 0 | |
| High BAALC expression | 82 | 20 | 77 (54, 90) | 19 | 91 (54, 99) | 18 | 7 (0, 21) | |
| P | 1.00 | .225 | .48 | .5 | ||||
| Intermediate-risk patients | 101 (46) | |||||||
| Low BAALC expression | 95 | 51 | 97 (85, 99) | 44 | 96 (79, 99) | 43 | 3 (0, 9) | |
| High BAALC expression | 84 | 50 | 90 (79, 96) | 46 | 87 (71, 94) | 45 | 11 (2, 23) | |
| P | .062 | .143 | .158 | .15 | ||||
| High-risk patients | 81 (37) | |||||||
| Low BAALC expression | 81 | 40 | 59 (35, 76) | 31 | 90 (66, 97) | 31 | 9 (0, 20) | |
| High BAALC expression | 72 | 41 | 47 (25, 66) | 31 | 53 (28, 72) | 28 | 41 (11, 62) | |
| P | .432 | .237 | .019* | .019* | ||||
| . | No. (%) . | CR % . | OS . | DFS . | CIR . | |||
|---|---|---|---|---|---|---|---|---|
| No. . | 5-y % (95% CI) . | No. . | 5-y % (95% CI) . | No. . | 5-y % (95% CI) . | |||
| All patients | 221 (100) | |||||||
| Low BAALC expression | 89 | 110 | 82 (70, 90) | 89 | 95 (86, 98) | 87 | 5 (1, 10) | |
| High BAALC expression | 79 | 111 | 73 (63, 81) | 96 | 78 (66, 86) | 91 | 21 (11, 30) | |
| P | .067 | .077 | .009* | .01* | ||||
| Low-risk patients | 39 (17) | |||||||
| Low BAALC expression | 87 | 19 | 93 (63, 99) | 14 | 100 | 13 | 0 | |
| High BAALC expression | 82 | 20 | 77 (54, 90) | 19 | 91 (54, 99) | 18 | 7 (0, 21) | |
| P | 1.00 | .225 | .48 | .5 | ||||
| Intermediate-risk patients | 101 (46) | |||||||
| Low BAALC expression | 95 | 51 | 97 (85, 99) | 44 | 96 (79, 99) | 43 | 3 (0, 9) | |
| High BAALC expression | 84 | 50 | 90 (79, 96) | 46 | 87 (71, 94) | 45 | 11 (2, 23) | |
| P | .062 | .143 | .158 | .15 | ||||
| High-risk patients | 81 (37) | |||||||
| Low BAALC expression | 81 | 40 | 59 (35, 76) | 31 | 90 (66, 97) | 31 | 9 (0, 20) | |
| High BAALC expression | 72 | 41 | 47 (25, 66) | 31 | 53 (28, 72) | 28 | 41 (11, 62) | |
| P | .432 | .237 | .019* | .019* | ||||
Summary of outcomes of patients with APL according to BAALC expression (in total cohort, and according to PETHEMA/GIMEMA criteria for relapse).22
CI, confidence interval; CIR, cumulative incidence of relapse; CR, complete remission.
Statistically significant differences (P < .05).